{"id":389847,"date":"2022-04-15T00:00:00","date_gmt":"2022-04-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0002-2022-biopharma-axial-spondyloarthritis-unmet-need-ankylosing-spondylitis-us-eu-2022\/"},"modified":"2026-03-31T10:39:46","modified_gmt":"2026-03-31T10:39:46","slug":"unneim0002-2022-biopharma-axial-spondyloarthritis-unmet-need-ankylosing-spondylitis-us-eu-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0002-2022-biopharma-axial-spondyloarthritis-unmet-need-ankylosing-spondylitis-us-eu-2022\/","title":{"rendered":"Axial Spondyloarthritis | Unmet Need | Ankylosing Spondylitis | US\/EU | 2022"},"content":{"rendered":"<p>In the last 20 years, TNF-\u03b1 inhibitors (AbbVie\u2019s Humira, Amgen \/ Pfizer\u2019s Enbrel, Janssen\u2019s Remicade and Simponi, UCB\u2019s Cimzia) have transformed the treatment of ankylosing spondylitis (AS) and brought new attention to this autoimmune disease. The IL-17 inhibitors (Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz) offer an alternative mechanism of action to TNF-\u03b1 inhibition and are relatively new to the market. Today, oral targeted therapies\u2014e.g., JAK inhibitors (AbbVie\u2019s Rinvoq and Pfizer\u2019s Xeljanz)\u2014are approved for AS; these agents\u2019 success will be shaped by the remaining unmet needs in the treatment of this population. In this report, we examine areas of unmet need in the treatment of AS, including short-term efficacy, patients\u2019 quality of life, mechanism of action, safety and tolerability, delivery, and price. With quantitative insight into U.S. and European rheumatologists\u2019 assessment of the unmet need in AS, we discuss the commercial opportunities for this enigmatic indication and how emerging therapies may capitalize on these opportunities.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for AS?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for AS?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in AS?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new AS drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.<\/p>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European rheumatologists fielded in February 2022.<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Amgen, Janssen, UCB, Novartis, Eli Lilly<\/p>\n<p><strong>Key drugs:<\/strong> Humira, Enbrel, Remicade, Cimzia, Cosentyx, Taltz, Rinvoq<\/p>\n","protected":false},"template":"","class_list":["post-389847","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389847\/revisions"}],"predecessor-version":[{"id":392972,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389847\/revisions\/392972"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}